Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:20:38.870Z.
Calculation as of: 2026-10-06T14:20:38.870Z.
Quote observation: 2026-10-06T14:20:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ce14650c18fa49a41504767bbd6ec089d5034b69e4d808542ce8aeb5b63776d1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$156.62M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.53M
EV/FCF Ratio
N/A
TTM Avg
69.69x
3Y Avg
69.69x
5Y Avg
69.69x
Market Cap
$162.23M
EV/FCF Ratio
N/A
TTM Avg
568.17x
3Y Avg
568.17x
5Y Avg
88.75x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $156.77M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $156.15M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $157.84M | N/A | 55.26x | 38.45x | 50.33x |
| Minerva Neurosciences, Inc. (NERV)vs › | $154.53M | N/A | 69.69x | 69.69x | 69.69x |
| Codexis, Inc. (CDXS)vs › | $151.66M | N/A | 40.01x | 40.01x | 40.01x |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | N/A | 568.17x | 568.17x | 88.75x |
| Korsana Biosciences, Inc. (KRSA)vs › | $147.21M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.54M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
